Please use this identifier to cite or link to this item:
https://ahro.austin.org.au/austinjspui/handle/1/9821
Title: | Extracellular nucleotide signaling by P2 receptors inhibits IL-12 and enhances IL-23 expression in human dendritic cells: a novel role for the cAMP pathway. | Austin Authors: | Schnurr, Max;Toy, Tracey;Shin, Amanda;Wagner, Moritz;Cebon, Jonathan S ;Maraskovsky, Eugene | Affiliation: | Ludwig Institute for Cancer Research, Austin Health, Heidelberg, Victoria 3084, Australia | Issue Date: | 14-Oct-2004 | Publication information: | Blood 2004; 105(4): 1582-9 | Abstract: | The interleukin-12 (IL-12) cytokine family plays important roles in the orchestration of innate and adaptive immunity by dendritic cells (DCs). The regulation of IL-12 expression has been thoroughly studied, but little is known about factors governing the expression of IL-23 and IL-27, 2 novel IL-12 family members acting on memory and naive T cells, respectively. We report that the expression of these cytokines by DCs was critically dependent on the mode of activation. DC activation by CD40L predominantly induced IL-12. Ligands of the Toll-like receptor (TLR) 3 and TLR4 induced IL-12 and IL-27, whereas exposure to intact Escherichia coli resulted in high expression of IL-12, IL-27, and IL-23. The nucleotide adenosine triphosphate (ATP) has been shown to inhibit IL-12 production by P2 receptors. We found that ATP also inhibited IL-27 expression but enhanced IL-23 expression. Interestingly, the reciprocal regulation of IL-12/IL-27 and IL-23 by ATP was mediated by 2 distinct P2 receptors and was also induced by prostaglandin E(2) by cyclic adenosine monophosphate (cAMP)-elevating EP2/EP4 receptors. As a consequence, DCs were selectively impaired in their ability to induce interferon-gamma (IFN-gamma) in naive T cells but continued to promote IFN-gamma and IL-17 production in memory T cells. These studies identify P2 receptors as promising targets for the design of novel strategies to manipulate specific stages of T-cell responses and to treat IL-12- and IL-23-mediated disorders. | Gov't Doc #: | 15486065 | URI: | https://ahro.austin.org.au/austinjspui/handle/1/9821 | DOI: | 10.1182/blood-2004-05-1718 | Journal: | Blood | URL: | https://pubmed.ncbi.nlm.nih.gov/15486065 | Type: | Journal Article | Subjects: | Adenosine Triphosphate.pharmacology.physiology Animals Cells, Cultured Cyclic AMP.physiology Dendritic Cells.immunology.metabolism.secretion Down-Regulation.immunology Escherichia coli.immunology Extracellular Space.metabolism.physiology G0 Phase.immunology Humans Immunologic Memory Interferon-gamma.antagonists & inhibitors.biosynthesis Interleukin-12.antagonists & inhibitors.biosynthesis Interleukin-23 Interleukin-23 Subunit p19 Interleukins.biosynthesis.secretion Mice Monocytes.immunology.metabolism.secretion Orthomyxoviridae.immunology Receptors, Purinergic P2.physiology Signal Transduction.immunology T-Lymphocyte Subsets.cytology.immunology.metabolism Up-Regulation.immunology |
Appears in Collections: | Journal articles |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
15486065.pdf | 358 kB | Adobe PDF | View/Open |
Page view(s)
16
checked on Nov 24, 2024
Download(s)
136
checked on Nov 24, 2024
Google ScholarTM
Check
Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.